This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Kutscherauer P, Kodym R, Bartaskova D.Cost-effectiveness analysis of add-on aliskiren to losartan treatment for patients with type 2 diabetes, hypertension and nephropathy in the Czech patients from payor perspective. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research: 154 abstr. PCV72, 16 May 2009. Available from: URL: http://www3.interscience.wiley.com
Rights and permissions
About this article
Cite this article
Adding aliskiren to losartan therapy in hypertensive patients with type 2 diabetes mellitus and nephropathy is cost effective. Pharmacoecon. Outcomes News 580, 9 (2009). https://doi.org/10.2165/00151234-200905800-00020
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905800-00020